Shen Fang, Zhou Hui
Department of Pediatrics, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education (MOE), Chengdu, Sichuan, China.
Front Neurosci. 2024 Nov 26;18:1459582. doi: 10.3389/fnins.2024.1459582. eCollection 2024.
Becker muscular dystrophy (BMD) is an X-linked recessive inherited disorder characterized by slowly progressing muscle weakness of the legs and pelvis, caused by mutations in the DMD gene, which encodes dystrophin protein. Different from Duchenne Muscular Dystrophy (DMD), in which dystrophin is completely absent in muscle tissue, while in BMD, the dystrophin gene can express some protein, but not enough. It has also been shown that a proportion of patients with DMD suffer from attention deficit hyperactivity disorder (ADHD), and the use of the stimulant methylphenidate has been suggested for the treatment of patients with DMD in combination with ADHD. However, there are no case reports on the treatment of co-occurring ADHD in BMD.
The patient was a 9-year-old boy who presented with elevated serum creatine kinase levels and inattention. The magnetic resonance imaging of the thigh muscles of both lower limbs suggested partial fatty infiltration of the gluteus maximus muscle bilaterally, and a novel heterozygous mutation (c.31 + 6 T > C) was identified in the DMD gene by Next Generation Sequencing (NGS) and the sequencing results were verified by using the Sanger method. The child was also diagnosed with co-morbid ADHD after a thorough evaluation and considering this new diagnosis, we started treatment with methylphenidate at a dose of 18 mg/day, and after 6 months of treatment, he showed a significant improvement in his attention span.
We identified a novel heterozygous mutation in the DMD gene, which will expand the spectrum of pathogenic variants in BMD. Simultaneously, methylphenidate treatment significantly improved attention in children with BMD co-morbid with ADHD, and this study provides value for future therapeutic protocols for BMD combined with ADHD. However, to the best of our knowledge, this is the only reported case report on the treatment of BMD co-morbid ADHD. So further studies are needed to determine the interrelationship between these disorders and their treatment.
贝克尔肌营养不良症(BMD)是一种X连锁隐性遗传性疾病,其特征为腿部和骨盆肌肉无力进展缓慢,由编码抗肌萎缩蛋白的DMD基因突变引起。与杜氏肌营养不良症(DMD)不同,DMD患者肌肉组织中完全缺乏抗肌萎缩蛋白,而在BMD中,抗肌萎缩蛋白基因可表达一些蛋白,但数量不足。也有研究表明,一部分DMD患者患有注意力缺陷多动障碍(ADHD),有人建议使用兴奋剂哌甲酯治疗合并ADHD的DMD患者。然而,目前尚无关于BMD合并ADHD治疗的病例报告。
该患者为一名9岁男孩,表现为血清肌酸激酶水平升高及注意力不集中。双下肢大腿肌肉的磁共振成像显示双侧臀大肌部分脂肪浸润,通过下一代测序(NGS)在DMD基因中鉴定出一种新的杂合突变(c.31 + 6 T > C),并使用桑格法验证了测序结果。经过全面评估,该患儿还被诊断为合并ADHD,考虑到这一新诊断,我们开始以18毫克/天的剂量使用哌甲酯进行治疗,治疗6个月后,他的注意力持续时间有了显著改善。
我们在DMD基因中鉴定出一种新的杂合突变,这将扩大BMD致病变异的范围。同时,哌甲酯治疗显著改善了合并ADHD的BMD患儿的注意力,本研究为未来BMD合并ADHD的治疗方案提供了参考价值。然而,据我们所知,这是唯一一篇关于BMD合并ADHD治疗的病例报告。因此,需要进一步研究以确定这些疾病之间的相互关系及其治疗方法。